The effect of Mocozift® syrup on patients with COVID-19

Phase 4

Recruiting

• Conditions: COVID-19 infection.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20221019056241N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 184

Inclusion Criteria

Age older than 18 years
Confirmed COVID-19 infection using PCR test
Prescription of Remdesivir for outpatient use
Avoiding use of other traditional medicine or supplements during the trial
signing the informed consent form

Exclusion Criteria

Participating in other clinical trials
History of hypersensitivity reactions to natural or herbal medicines

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The score of dyspnea severity according to Modified Medical Research Council Dyspnea Scale. Timepoint: One day before medicinal intervention and fifth day of intervention. Method of measurement: Modified Medical Research Council Dyspnea Scale.;Cough severity. Timepoint: One day before medicinal intervention and fifth day of intervention. Method of measurement: Cough visual analogue scale.;Appetite. Timepoint: One day before medicinal intervention and fifth day of intervention. Method of measurement: Simplified Nutritional Appetite Questionnaire (SNAQ).;Fatigue severity. Timepoint: One day before medicinal intervention and fifth day of intervention. Method of measurement: Fatigue Severity Scale (FSS).